Global Biosimilar Drug Market Size and Forecast to 2021
Biosimilar Drug Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and comprehensive research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom,Japan, South Korea and China).
In this report, the global Biosimilar Drug market is valued at USD XX million in 2017 and is projected to reach USD XX million by the end of 2021, growing at a CAGR of XX% during the period 2017 to 2021.
The report firstly introduced the Biosimilar Drug basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.
The major players profiled in this report include:
Hengrui Medicine
Hisun Pharm
MSD
Pfizer
Novartis
Boehringer
The end users/applications and product categories analysis:
On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-
mAbs (Monoclonal Antibodies)
FC-Fusion Proteins
EPO (Erythropoietin)
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Biosimilar Drug for each application, including
Oncology
Diabetes
Rheumatoid arthritis
In this report, the global Biosimilar Drug market is valued at USD XX million in 2017 and is projected to reach USD XX million by the end of 2021, growing at a CAGR of XX% during the period 2017 to 2021.
The report firstly introduced the Biosimilar Drug basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.
The major players profiled in this report include:
Hengrui Medicine
Hisun Pharm
MSD
Pfizer
Novartis
Boehringer
The end users/applications and product categories analysis:
On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-
mAbs (Monoclonal Antibodies)
FC-Fusion Proteins
EPO (Erythropoietin)
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Biosimilar Drug for each application, including
Oncology
Diabetes
Rheumatoid arthritis
PART I BIOSIMILAR DRUG INDUSTRY OVERVIEW
CHAPTER ONE BIOSIMILAR DRUG INDUSTRY OVERVIEW
1.1 Biosimilar Drug Definition
1.2 Biosimilar Drug Classification and Product Type Analysis
mAbs (Monoclonal Antibodies)
FC-Fusion Proteins
EPO (Erythropoietin)
1.3 Biosimilar Drug Application and Down Stream Market Analysis
Oncology
Diabetes
Rheumatoid arthritis
1.4 Biosimilar Drug Industry Chain Structure Analysis
1.5 Biosimilar Drug Industry Development Overview
1.6 Biosimilar Drug Global Market Comparison Analysis
1.6.1 Biosimilar Drug Global Import Market Analysis
1.6.2 Biosimilar Drug Global Export Market Analysis
1.6.3 Biosimilar Drug Global Main Region Market Analysis
1.6.4 Biosimilar Drug Global Market Comparison Analysis
1.6.5 Biosimilar Drug Global Market Development Trend Analysis
PART II ASIA BIOSIMILAR DRUG INDUSTRY (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER TWO 2012-2017 ASIA BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
2.1 2012-2017 Biosimilar Drug Capacity Production Overview
2.2 2012-2017 Biosimilar Drug Production Market Share Analysis
2.3 2012-2017 Biosimilar Drug Demand Overview
2.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
2.5 2012-2017 Biosimilar Drug Import Export Consumption Analysis
2.6 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER THREE ASIA BIOSIMILAR DRUG KEY MANUFACTURERS ANALYSIS
3.1 Hengrui Medicine
3.1.1 Product Picture and Specification
3.1.2 Capacity Production Price Cost Production Value Analysis
3.1.3 Contact Information
3.2 Hisun Pharm
3.2.1 Product Picture and Specification
3.2.2 Capacity Production Price Cost Production Value Analysis
3.2.3 Contact Information
3.3 Company C
3.3.1 Product Picture and Specification
3.3.2 Capacity Production Price Cost Production Value Analysis
3.3.3 Contact Information
CHAPTER FOUR ASIA BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
4.1 2017-2021 Biosimilar Drug Capacity Production Trend
4.2 2017-2021 Biosimilar Drug Production Market Share Analysis
4.3 2017-2021 Biosimilar Drug Demand Trend
4.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
4.5 2017-2021 Biosimilar Drug Import Export Consumption Analysis
4.6 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
PART III NORTH AMERICAN BIOSIMILAR DRUG INDUSTRY (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER FIVE 2012-2017 NORTH AMERICAN BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
5.1 2012-2017 Biosimilar Drug Capacity Production Overview
5.2 2012-2017 Biosimilar Drug Production Market Share Analysis
5.3 2012-2017 Biosimilar Drug Demand Overview
5.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
5.5 2012-2017 Biosimilar Drug Import Export Consumption Analysis
5.6 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER SIX NORTH AMERICAN BIOSIMILAR DRUG KEY MANUFACTURERS ANALYSIS
6.1 MSD
6.1.1 Product Picture and Specification
6.1.2 Capacity Production Price Cost Production Value Analysis
6.1.3 Contact Information
6.2 Pfizer
6.2.1 Product Picture and Specification
6.2.2 Capacity Production Price Cost Production Value Analysis
6.2.3 Contact Information
CHAPTER SEVEN NORTH AMERICAN BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
7.1 2017-2021 Biosimilar Drug Capacity Production Trend
7.2 2017-2021 Biosimilar Drug Production Market Share Analysis
7.3 2017-2021 Biosimilar Drug Demand Trend
7.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
7.5 2017-2021 Biosimilar Drug Import Export Consumption Analysis
7.6 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
PART IV EUROPE BIOSIMILAR DRUG INDUSTRY ANALYSIS (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER EIGHT 2012-2017 EUROPE BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
8.1 2012-2017 Biosimilar Drug Capacity Production Overview
8.2 2012-2017 Biosimilar Drug Production Market Share Analysis
8.3 2012-2017 Biosimilar Drug Demand Overview
8.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
8.5 2012-2017 Biosimilar Drug Import Export Consumption Analysis
8.6 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER NINE EUROPE BIOSIMILAR DRUG KEY MANUFACTURERS ANALYSIS
9.1 Novartis
9.1.1 Product Picture and Specification
9.1.2 Capacity Production Price Cost Production Value Analysis
9.1.3 Contact Information
9.2 Boehringer
9.2.1 Product Picture and Specification
9.2.2 Capacity Production Price Cost Production Value Analysis
9.2.3 Contact Information
CHAPTER TEN EUROPE BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
10.1 2017-2021 Biosimilar Drug Capacity Production Trend
10.2 2017-2021 Biosimilar Drug Production Market Share Analysis
10.3 2017-2021 Biosimilar Drug Demand Trend
10.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
10.5 2017-2021 Biosimilar Drug Import Export Consumption Analysis
10.6 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
PART V BIOSIMILAR DRUG MARKETING CHANNELS AND INVESTMENT FEASIBILITY
CHAPTER ELEVEN BIOSIMILAR DRUG MARKETING CHANNELS DEVELOPMENT PROPOSALS ANALYSIS
11.1 Biosimilar Drug Marketing Channels Status
11.2 Biosimilar Drug Marketing Channels Characteristic
11.3 Biosimilar Drug Marketing Channels Development Trend
11.2 New Firms Enter Market Strategy
11.3 New Project Investment Proposals
CHAPTER TWELVE DEVELOPMENT ENVIRONMENTAL ANALYSIS
12.1 China Macroeconomic Environment Analysis
12.2 European Economic Environmental Analysis
12.3 United States Economic Environmental Analysis
12.4 Japan Economic Environmental Analysis
12.5 Global Economic Environmental Analysis
CHAPTER THIRTEEN BIOSIMILAR DRUG NEW PROJECT INVESTMENT FEASIBILITY ANALYSIS
13.1 Biosimilar Drug Market Analysis
13.2 Biosimilar Drug Project SWOT Analysis
13.3 Biosimilar Drug New Project Investment Feasibility Analysis
PART VI GLOBAL BIOSIMILAR DRUG INDUSTRY CONCLUSIONS
CHAPTER FOURTEEN 2012-2017 GLOBAL BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
14.1 2012-2017 Biosimilar Drug Capacity Production Overview
14.2 2012-2017 Biosimilar Drug Production Market Share Analysis
14.3 2012-2017 Biosimilar Drug Demand Overview
14.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
14.5 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER FIFTEEN GLOBAL BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
15.1 2017-2021 Biosimilar Drug Capacity Production Trend
15.2 2017-2021 Biosimilar Drug Production Market Share Analysis
15.3 2017-2021 Biosimilar Drug Demand Trend
15.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
15.5 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER SIXTEEN GLOBAL BIOSIMILAR DRUG INDUSTRY RESEARCH CONCLUSIONS
CHAPTER ONE BIOSIMILAR DRUG INDUSTRY OVERVIEW
1.1 Biosimilar Drug Definition
1.2 Biosimilar Drug Classification and Product Type Analysis
mAbs (Monoclonal Antibodies)
FC-Fusion Proteins
EPO (Erythropoietin)
1.3 Biosimilar Drug Application and Down Stream Market Analysis
Oncology
Diabetes
Rheumatoid arthritis
1.4 Biosimilar Drug Industry Chain Structure Analysis
1.5 Biosimilar Drug Industry Development Overview
1.6 Biosimilar Drug Global Market Comparison Analysis
1.6.1 Biosimilar Drug Global Import Market Analysis
1.6.2 Biosimilar Drug Global Export Market Analysis
1.6.3 Biosimilar Drug Global Main Region Market Analysis
1.6.4 Biosimilar Drug Global Market Comparison Analysis
1.6.5 Biosimilar Drug Global Market Development Trend Analysis
PART II ASIA BIOSIMILAR DRUG INDUSTRY (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER TWO 2012-2017 ASIA BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
2.1 2012-2017 Biosimilar Drug Capacity Production Overview
2.2 2012-2017 Biosimilar Drug Production Market Share Analysis
2.3 2012-2017 Biosimilar Drug Demand Overview
2.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
2.5 2012-2017 Biosimilar Drug Import Export Consumption Analysis
2.6 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER THREE ASIA BIOSIMILAR DRUG KEY MANUFACTURERS ANALYSIS
3.1 Hengrui Medicine
3.1.1 Product Picture and Specification
3.1.2 Capacity Production Price Cost Production Value Analysis
3.1.3 Contact Information
3.2 Hisun Pharm
3.2.1 Product Picture and Specification
3.2.2 Capacity Production Price Cost Production Value Analysis
3.2.3 Contact Information
3.3 Company C
3.3.1 Product Picture and Specification
3.3.2 Capacity Production Price Cost Production Value Analysis
3.3.3 Contact Information
CHAPTER FOUR ASIA BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
4.1 2017-2021 Biosimilar Drug Capacity Production Trend
4.2 2017-2021 Biosimilar Drug Production Market Share Analysis
4.3 2017-2021 Biosimilar Drug Demand Trend
4.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
4.5 2017-2021 Biosimilar Drug Import Export Consumption Analysis
4.6 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
PART III NORTH AMERICAN BIOSIMILAR DRUG INDUSTRY (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER FIVE 2012-2017 NORTH AMERICAN BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
5.1 2012-2017 Biosimilar Drug Capacity Production Overview
5.2 2012-2017 Biosimilar Drug Production Market Share Analysis
5.3 2012-2017 Biosimilar Drug Demand Overview
5.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
5.5 2012-2017 Biosimilar Drug Import Export Consumption Analysis
5.6 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER SIX NORTH AMERICAN BIOSIMILAR DRUG KEY MANUFACTURERS ANALYSIS
6.1 MSD
6.1.1 Product Picture and Specification
6.1.2 Capacity Production Price Cost Production Value Analysis
6.1.3 Contact Information
6.2 Pfizer
6.2.1 Product Picture and Specification
6.2.2 Capacity Production Price Cost Production Value Analysis
6.2.3 Contact Information
CHAPTER SEVEN NORTH AMERICAN BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
7.1 2017-2021 Biosimilar Drug Capacity Production Trend
7.2 2017-2021 Biosimilar Drug Production Market Share Analysis
7.3 2017-2021 Biosimilar Drug Demand Trend
7.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
7.5 2017-2021 Biosimilar Drug Import Export Consumption Analysis
7.6 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
PART IV EUROPE BIOSIMILAR DRUG INDUSTRY ANALYSIS (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER EIGHT 2012-2017 EUROPE BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
8.1 2012-2017 Biosimilar Drug Capacity Production Overview
8.2 2012-2017 Biosimilar Drug Production Market Share Analysis
8.3 2012-2017 Biosimilar Drug Demand Overview
8.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
8.5 2012-2017 Biosimilar Drug Import Export Consumption Analysis
8.6 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER NINE EUROPE BIOSIMILAR DRUG KEY MANUFACTURERS ANALYSIS
9.1 Novartis
9.1.1 Product Picture and Specification
9.1.2 Capacity Production Price Cost Production Value Analysis
9.1.3 Contact Information
9.2 Boehringer
9.2.1 Product Picture and Specification
9.2.2 Capacity Production Price Cost Production Value Analysis
9.2.3 Contact Information
CHAPTER TEN EUROPE BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
10.1 2017-2021 Biosimilar Drug Capacity Production Trend
10.2 2017-2021 Biosimilar Drug Production Market Share Analysis
10.3 2017-2021 Biosimilar Drug Demand Trend
10.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
10.5 2017-2021 Biosimilar Drug Import Export Consumption Analysis
10.6 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
PART V BIOSIMILAR DRUG MARKETING CHANNELS AND INVESTMENT FEASIBILITY
CHAPTER ELEVEN BIOSIMILAR DRUG MARKETING CHANNELS DEVELOPMENT PROPOSALS ANALYSIS
11.1 Biosimilar Drug Marketing Channels Status
11.2 Biosimilar Drug Marketing Channels Characteristic
11.3 Biosimilar Drug Marketing Channels Development Trend
11.2 New Firms Enter Market Strategy
11.3 New Project Investment Proposals
CHAPTER TWELVE DEVELOPMENT ENVIRONMENTAL ANALYSIS
12.1 China Macroeconomic Environment Analysis
12.2 European Economic Environmental Analysis
12.3 United States Economic Environmental Analysis
12.4 Japan Economic Environmental Analysis
12.5 Global Economic Environmental Analysis
CHAPTER THIRTEEN BIOSIMILAR DRUG NEW PROJECT INVESTMENT FEASIBILITY ANALYSIS
13.1 Biosimilar Drug Market Analysis
13.2 Biosimilar Drug Project SWOT Analysis
13.3 Biosimilar Drug New Project Investment Feasibility Analysis
PART VI GLOBAL BIOSIMILAR DRUG INDUSTRY CONCLUSIONS
CHAPTER FOURTEEN 2012-2017 GLOBAL BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
14.1 2012-2017 Biosimilar Drug Capacity Production Overview
14.2 2012-2017 Biosimilar Drug Production Market Share Analysis
14.3 2012-2017 Biosimilar Drug Demand Overview
14.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
14.5 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER FIFTEEN GLOBAL BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
15.1 2017-2021 Biosimilar Drug Capacity Production Trend
15.2 2017-2021 Biosimilar Drug Production Market Share Analysis
15.3 2017-2021 Biosimilar Drug Demand Trend
15.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
15.5 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER SIXTEEN GLOBAL BIOSIMILAR DRUG INDUSTRY RESEARCH CONCLUSIONS
